Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (16005)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 26, 2015 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Meta-Analysis
ISSN
2308-3840
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shihab HM, Akande T, Armstrong K, Singh S, Loke YK. Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials. World J Meta-Anal 2015; 3(6): 254-283 [DOI: 10.13105/wjma.v3.i6.254] |
|---|---|
| URL: | https://www.wjgnet.com/2308-3840/full/v3/i6/254.htm |
| Number | Citing Articles |
| 1 |
Yu Hong Chen, Chien‐Ning Huang, Young Min Cho, Pengfei Li, Liqun Gu, Feng Wang, Jun Yang, Wei Qing Wang. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial. Diabetes, Obesity and Metabolism 2018; 20(9): 2121 doi: 10.1111/dom.13340
|
| 2 |
Wissam Ghusn, Maria D. Hurtado. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars 2024; 12: 100127 doi: 10.1016/j.obpill.2024.100127
|